Immune-Related Adverse Events with Cancer Immunotherapy: Case-Based Challenges for the Oncology Nurse

October 7, 2020

Early identification of irAEs and initiation of systemic immunosuppression can improve outcomes without compromising the efficacy of immune checkpoint inhibition. As front-line caregivers, oncology nurses are optimally positioned to quickly identify such adverse events and employ appropropriate management strategies. The objective of this educational initiative is to provide oncology nurses and nurse practitioners attending Oncology Nursing Society’s (ONS) regional chapter meetings with evidence-based information on the latest developments in the use of cancer immunotherapy and effective management of irAEs.


This activity is presented by Creative Educational Concepts and supported by an independent educational grant from Merck Sharp & Dohme Corp.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Learning Objectives

  • Assess the clinical efficacy, unique response patterns, and safety profiles associated with checkpoint inhibitors in various types of cancers.
  • Evaluate the signs and symptoms of immune-related adverse events (irAEs) associated with checkpoint inhibitors and understand how to differentiate these from other etiologies.
  • Review recent ASCO/NCCN guidelines for the management of irAEs and apply these recommendations to optimize patient care.
  • Using a case-based approach, discuss strategies oncology nurses can employ to overcome real-world challenges to the early recognition and appropriate management of irAEs.
Course summary
Available credit: 
  • 1.00 ANCC
    In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity is designated for 1.00 contact hour.
  • 1.00 Participation
Course opens: 
08/03/2020
Course expires: 
11/07/2020
Event starts: 
10/07/2020 - 7:30pm
Event ends: 
10/07/2020 - 8:30pm
Rating: 
0

5 min  

Welcome and Introductions/Pre-activity Assessment

50 min   

A Whole New World: The Evolving Role of Checkpoint Inhibitors in Cancer Therapy

Immune-Related Adverse Events: Key Considerations for the Oncology Nurse

Case-based Challenges in irAE Management

5 min 

Faculty/Audience Q&A/Post-test

Live Virtual Event
Suffolk ONS Chapter
7:30pm EDT
United States

Susan McCall, MSN, ANP-BC, AOCNP
Advanced Practice Provider Manager
Leukemia Service, Department of Nursing
Memorial Sloan Kettering Cancer Center
New York, New York


 


Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:

Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:

Stephanie Andrews, MS, ANP-BC–has disclosed that she is a consultant for OncoSec and Daiichi Sankyo. 

Susan J. McCall, MSN, ANP-BC, AOCNP–has disclosed that she is a consultant for AstraZeneca, Advisory Board.

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP–has disclosed that she is a consultant for AstraZeneca.

Peer Reviewer:

RuthAnn Gordon, MSN, FNP-BC, RN, OCN–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

Available Credit

  • 1.00 ANCC
    In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity is designated for 1.00 contact hour.
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

Zoom